Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Merck Q3 2026 Earnings Analysis cover art

Merck Q3 2026 Earnings Analysis

Merck Q3 2026 Earnings Analysis

Listen for free

View show details
About this listen
More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Merck's third quarter 2026 results, reported this past Thursday.

**ALEX:** Before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Good to have that squared away. So Alex, Merck's a company everyone's watching right now because of the Keytruda patent cliff looming. What'd the quarter actually look like?

**ALEX:** Solid, honestly. Revenue came in at $18.1 billion, up 5% year-over-year, or 4% excluding currency effects. And they actually narrowed and raised the midpoint of their full-year guidance — now expecting $66.8 to $67.3 billion in revenue and EPS of $2.77 to $2.82.

**JORDAN:** That's a good sign. Companies don't usually raise guidance if they're nervous about the quarter. Let's talk Keytruda specifically, since that's the elephant in the room.

**ALEX:** Right, the Keytruda franchise — including the newer subcutaneous version, Keytruda Qlex — grew 6% to $8.6 billion. Still their biggest product by a mile. But management was candid: they're now approaching peak revenues in certain indications, and growth is moderating as they've basically saturated the eligible patient population.

**JORDAN:** And that subcutaneous version, Qlex, is actually really interesting as its own story. $830 million in sales this quarter, and there's litigation drama in Europe — a Dutch court issued an injunction over hyaluronidase IP that's blocking sales in several smaller European markets.

**ALEX:** Yeah, but CEO Robert Davis was pretty firm that this doesn't change their confidence. The U.S. business is humming — they're targeting 30-40% subcutaneous adoption by end of 2027, and the affected European markets are described as lower-volume anyway.

**JORDAN:** Okay, so that's the "today" story. But the real headline for me is what they said about 2027 — because that's when the real Keytruda cliff pressure, plus generic competition for Bridion and Januvia, starts biting.

**ALEX:** CFO Caroline Litchfield called it directly: more than $2 billion in headwinds next year from generics hitting Bridion, the Januvia family, and Adempas. Plus continued Keytruda moderation and some German pricing policy pressure.

**JORDAN:** But — and this is the part I think investors should really sit with — she described 2027 as "a year of investment," not decline. They're framing the whole Keytruda loss-of-exclusivity period as more of a "hill" in revenue rather than a cliff, with earnings expected to largely mirror that shallow dip and then resume growth.

**ALEX:** That's the bet they're making. And it's backed by what might be the most exciting part of this whole call — the pipeline news out of the ESMO oncology conference last weekend.

**JORDAN:** Walk us through it, because there were a lot of acronyms flying around.

**ALEX:** The biggest one: sac-TMT, their antibody-drug conjugate, showed nearly a 7-month improvement in median overall survival for endometrial cancer patients compared to chemo alone. That's a disease with rising incidence and a really poor prognosis, so that's meaningful.

**JORDAN:** And then there's entismodigene — the individualized mRNA cancer vaccine they're developing with Moderna. This one actually got some strong outside validation.

**ALEX:** Right, Dean Li, their research chief, quoted oncologist Antoni Ribas calling the melanoma data "a landmark in cancer drug development." It showed meaningful improvements in recurrence-free survival when combined with Keytruda in resected melanoma patients. They're now talking with the FDA about filing it.

This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet